Solitary fibrous tumors are an uncommon sarcoma type characterized by NAB2-STAT6 gene fusion. While solitary fibrous tumors metastasize in 5-25% of cases, it has historically been challenging to determine which specific tumor and patient characteristics predict aggressive behavior. We previously reported on a novel risk stratification scheme for solitary fibrous tumors incorporating patient age, tumor size, and mitotic activity to predict risk of metastasis. Herein we validate this risk stratification scheme in an independent, lower-risk population of 79 patients with primary non-meningeal solitary fibrous tumors, and propose incorporating tumor necrosis as a fourth variable to further improve the risk score. Fifty-seven percent of cases were considered low risk, 29% intermediate risk, and 14% high risk for metastasis. Of 50 patients with sufficient clinical follow-up data, no metastases developed in the low-risk patients (n=23), while there was a 7% 10-year metastatic risk in the intermediate risk group (n=17), and a 49% 5-year metastatic risk for the high-risk patients (n=10). When tumor necrosis was added as a fourth variable to the model, predictive power was enhanced. Under the revised stratification, the proportion of tumors identified as low risk increased to 66%, with no metastasis at 10 years, intermediate risk cases comprised 24% with 10% risk of metastasis at 10 years, and high risk comprised 10% of cases with 73% risk of metastasis at 5 years. In Kaplan-Meier analysis, this fourth-variable stratification provided significant discrimination between the risk groups (P=0.0005). These findings confirmed the clinical utility of our previously published risk stratification model and support the inclusion of necrosis as a fourth variable in the model.

Overview Metabolic bone disease is highly prevalent among cancer patients, owing to the systemic effects of malignancy, the humoral response, and to commonly prescribed cancer therapies. Surgical approaches to acute fracture can drastically impact quality of life. The use of bone antiresorptive agents can prevent fractures in this population and can reduce bone pain in patients with skeletal metastases.

Overview The skeletal complications of cancer are highly prevalent. Bone metastases are present in approximately 70% of patients with cancer‐related deaths. Skeletal complications can present clinically as pain associated with bone metastases, pathologic fractures, or hypercalcemia. Additionally, several therapies for cancers may have deleterious effect on bone health such as aromatase inhibition in patients with breast cancer. The presence of skeletal metastases often indicates that cure from cancer unlikely. Goals of therapy may shift to palliation and to systemic control with possible prolonged survival. Surgical treatments, medical therapies, including antiresorptive agents, and/or radiation therapy should each be considered to achieve optimal care in patients with skeletal complications of cancer.

No abstract